Clinical Trials Logo

Clinical Trial Summary

This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04350736
Study type Interventional
Source Theravance Biopharma
Contact
Status Completed
Phase Phase 1
Start date April 23, 2020
Completion date July 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT04402866 - TD-0903 for ALI Associated With COVID-19 Phase 2